注射用雪莲质量控制方法及其在大鼠体内的药物动力学研究
详细信息    本馆镜像全文|  推荐本文 |  |   获取CNKI官网全文
摘要
天山雪莲收载于《中国药典》(2005年版一部),其药理作用有抗炎镇痛、抗衰老及抑制癌细胞增生等。随着天山雪莲现代药理研究的深入及其在抗风湿、类风湿性关节炎等临床上的应用,天山雪莲日益引起国内外药学工作者的关注。临床上已有雪莲注射液用于风湿性关节炎、类风湿性关节炎,疗效确切、可靠、毒副作用小。以天山雪莲药材为原料,采用现代科学技术手段,制成冻干粉针能够增强其的稳定性,因此研制了注射用雪莲(冻干)。本论文研究内容包括:(1)注射用雪莲(冻干)的制备;(2)注射用雪莲(冻干)指纹图谱的研究;(3)注射用雪莲(冻干)中指标成分分析方法及质量标准的建立;(4)注射用雪莲(冻干)稳定性研究;(5)注射用雪莲(冻干)在大鼠体内的药物动力学研究。
     经处方筛选和工艺优化,以天山雪莲提取液1000mL为原料,以150g甘露醇为支持剂,-40℃预冻5小时,-20℃减压干燥(<10Pa)5小时,将温度升至20℃,继续减压干燥6小时制得产品外形饱满、疏松,成型性好。
     使用C_(18)色谱柱,以乙腈-50mmol·L~(-1)KH_2PO_4水溶液(H_3PO_4调pH3.6)为流动相进行梯度洗脱,紫外法检测,建立了体现注射用雪莲(冻干)化学成分特征的HPLC指纹图谱。选用紫丁香苷为参照物,通过对10批注射用雪莲(冻干)供试品指纹图谱的分析,确定了13个共有指纹峰,建立了共有模式。相似度分析表明,10批供试品的相似度均大于0.95,说明注射用雪莲(冻干)制备工艺稳定,批间重现好。制剂、中间体和药材的指纹图谱具有很好的相关性。
     采用简便的TLC鉴别方法,以对照药材和芦丁为指标,对制剂进行了鉴别。采用高效液相色谱法和比色法建立了芦丁和总黄酮两种指标性成分的含量测定方法,方法可靠,重现性好。
     加速试验和留样试验结果表明,制剂的稳定性良好。
     建立了测定大鼠血浆中芦丁含量的反相高效液相色谱分析方法,以新北美圣草苷为内标,血浆经甲醇沉淀蛋白后进样分析。芦丁在0.050~3.2μg·mL~(-1)(r=0.9901)范围内线性关系良好。方法的定量下限为0.050μg·mL~(-1)。测定了芦丁的血药浓度-时间曲线,计算其相应的药物动力学参数。注射用雪莲(冻干)腹腔给药后,芦丁的C_(max)为1.410μg·mL~(-1),t_(max)为8.0 min,t_(1/2)为84.2 min,AUC_(0-∞)为131.6 mg·L~(-1)·min。
Saussurea involucrate ( Kar.et Kir.) Sch. Bip., listed in《Phamacopoeia of the People's Republic of China》(Edition 2005,Volumn I ) is a kind of ethnic medicine, possessing anti-inflamamation, analgesia, anti-aging and contraception. With its clinical application to the treatment rheumatic arthritis and rheumatoid arthritis, Saussurea involucrate ( Kar.et Kir.) Sch. Bip. increasingly attracts the attention of pharmaceutical researchers. Xuelian injection has definite therapeutic effectiveness. If Xuelian is prepared into freeze dried powder with modern technology, its stability must be enhanced. This study includes: (1) the preparation design of Xuelian for injection (2) the HPLC-finger-printing development of Xuelian for injection (3) quality control method of Xuelian for injection (4) the stability test of Xuelian for injection (5) the pharmacokinetics of Xuelian for injection in rats.The prescription and technological process were optimized by the criterion of appearance, moisture and resolubility. An good product was obtained with 300 mg mannitol each bottle. The optimized technological process is as follows: pre-freeze for 5 hours at -40℃, and then for 6 hours under vacuum at -20℃, raising the temperature to 20℃and drying for another 6 hours under vacuum.An HPLC-FP of Xuelian for injection was developed with C_(18) column employingCH_3CN-50mmol·L~(-1)KH_2PO_4(pH=3.6) as mobile phase for gradient elution with ultraviolet detection. Thirteen common peaks were achieved after analyzing 10 batches of Xuelian for injection, Syringin was choosed as the reference substance, and the HPLC-FP common pattern of Xuelian for injection was developed. The similarities of 10 batches of the samples were all above 0.95, indicating the preparation process of Xuelian for injection is reproducible. There is a good correlationship among HPLC-FP of Xuelian for injection, intermediate and Saussurea involucrate ( Kar.et Kir.) Sch. Bip..Standard herbs and rutin, as typical principles were qualitalively analyzed with simple and proper TLC methods. An HPLC method was developed to determine the content of rutin in the preparation. Flavonoids in the preparation were determined colourmetrically. All these methods are accurate and sensitive.
     The preparation was stable in the accelerated test and at room temperature.
     An RP-HPLC method was developed for the determination of rutin in plasma of rats after treated with Xuelian for injection intraperitoneaUy. After added Neoeriocitrin as internal standard, plasma samples were extracted with methanol. The linear range for rutin was 0.050~3.2μg·mL~(-1) (r=0.9901). The LLOQ was 0.050μg·mL~(-1). Both accuracy and precision of the assay were satisfactory. The plasma concentration-time curve of rutin was plotted and the pharmacokinetic parameters were calculated.
     The C_(max), t_(max), t_(1/2) and AUC_(0-∞) of rutin in rats were 1.410μg·mL~(-1), 8.0 min, 84.2 min and 131.6 mg·L~(-1)·min, respectively.
引文
[1] 甘师俊,李振吉,邹健强.中药现代化发展战略.北京:科学技术文献出版社,1998,14.
    [2] 赵新先.中药注射剂学.广州:广州科技出版社,2000,3-3.
    [3] 施怀生,冯俊生.中药注射剂创制考源.中华医史杂志,1995,25(2):107-107.
    [4] 范碧亭.中药药剂学.上海:上海科技出版社,1997,223-223.
    [5] 陈怡,罗顺德.注射用中药冻干粉针进展.中国药师,2003,6(11):743-745.
    [6] 谢培山.浅谈中药指纹图谱在新药研发中的作用.中国中西医结合杂志,2002,22(9):644.
    [7] EMEA. Final Proposals for Revision ofthr Note for Guidance on Quality of Herbal Remedies. 1998.
    [8] 谢培山.中药制剂色谱指纹图谱(图象)鉴别.中成药,2000,22(6):391-395.
    [9] Rudolf Bauer. Quality Criteria and Phytopharmaceutical: Can Acceptable Drug Standards be achieved. Drug Information Journal, 1998, 32: 101-110.
    [10] 谢培山.现代化中药产业关键技术系列研讨会(一)国际色谱指纹图谱评价中药质量研讨会学术报告论文集.广州,2001,31,27
    [11] 谢培山.中药色谱指纹图谱鉴别的概念、属性、技术与应用.中国中药杂志,2001,26(10):653-655.
    [12] 谢培山.中药色谱指纹图谱的应用.中国中药杂志,2001,26(11):693~695.
    [13] 毕开顺,李玉娟.中药材指纹图谱质量控制方法研究.广州 国际色谱指纹图谱评价中药质量研讨会论文集.2001,10-13.
    [14] 药注射剂色谱指纹图谱实验研究技术指南(试行).上海 中药指纹图谱会议.
    [15] 罗国安,王义明,曹进.多维多息特征谱及其应用.中成药,2000,22(6):395-397.
    [16] Yujuan. Li, Xinmiao. Liang, Hongbin. Xiao, Kaishun. Bi. Determination of spinosin in rat plasma after oral administration of Suanzaoren decoction by RP-HPLC. Journal of Chromatography B, 2003, 787(2): 421-425.
    [17] Zonghua, Song, Kalshun. Bi, and Xu Luo. An HPLC method for the determination and pharmacokinetic study of cinnamic acid in the plasma of rats having taken the traditional Chinese medicinal preparation in Ling-Gui-Zhu-Gan decoction. Journal of Chromatographic. Science, 2002, 40(4): 198-200.
    [18] Hongiian. Yang, Bo. Yuan, Lei. Li, Huashan. Chen, Famei. Li. HPLC determination and pharmacokinetics of chlorogenic acid in rabbit plasma after an oral dose of Flos Lonicerae extract Journal of Chromatographic Science, 2004, 42(3): 173-176.
    [19] Pickling B, Hans B and Kramaczyk R. Two high performance liquid chromatographic assays for the determination of flee and total silibinin diastereomers in plasma using column switching with electrochemical detection and reversed-phase chromatography with UV detection. Journal of Chromatography B, 1995, 18(2): 267-277.
    [20] J. Zhang, H. Yu, Y Sheng, et al. HPLC determination and pharmacokinetic study of salvianolic acid B in rat plasma after oral administration of Radix Salivia miltiorrhiza extract. Biomedical Chromatography, 2004, 19(1): 15-18.
    [21] 顾企民,韩悦,韩超,等.以氘标记同系物为内标的伪海南新碱药物动力学研究.中华肿瘤杂志,1992,13(6):51-53.
    [22] 雷丹青,廖共山.中华眼镜蛇蛇毒神经生长因子大鼠体内分布的研究.中国生化药物杂志,1997,18(3):137-138.
    [23] 朱龙祥,王清川,刘广芬.尖吻腹蛇毒凝血酶样酶的药代动力学.中国药理学与毒理学杂志,1987,1(5):353-356.
    [24] 李君山,蔡少青.雪莲花类药材的化学和药理研究进展中国药学杂志.1998,33(8):449-452.
    [25] 国家药典委员会.中华人民共和国药典:一部.北京:化工工业出版社,2005,35-36.
    [26] 谭敦炎,朱建雯,姚芳.雪莲的生殖生态学研究.新疆农业大学学报,1998,21(1):1-5.
    [27] 雪莲注射液使用说明书.新疆西域制药厂
    [28] 宋立人,洪恂,丁绪亮.现代中药学大辞典.北京:人民卫生出版社,2001:1921-1923.
    [29] 赵莉,王晓玲.新疆雪莲的化学成分、药理作用及其临床应用.西南民族大学学报·自然科学版,2003,29(4):424-428.
    [30] 张琦,伍红,张嫦.五种药用雪莲花中总黄酮及微量元素的测定和比较研究.华西药学杂志,1997,12(3):145-148.
    [31] 贾忠建,李瑜,杜牧.大苞雪莲挥发油成分的研究.兰州大学学报(自然科学版),1986,22(3):100-105.
    [32] 何新,李观海,陈汉瑜.新疆雪莲黄酮的抗炎镇痛作用及抗炎机理研究.西北药学杂志,1990,5(3):17-19.
    [33] 林秀珍,王国祥,王立斌,等.雪莲多糖对离体大鼠子宫的作用.药学学报,1986,21(6):220-223.
    [34] 郑荣梁,刘光顺,邢光新.大苞雪莲花多糖清除自由基及抗疲劳作用.中国药理学报,1993,14(11):47-49.
    [35] 黄辰,倪磊,胡劲松.雪莲黄酮总甙抑制染色体损伤与SOD活性的相关研究.西安医科大学学报,2000,12(2):93-94.
    [36] 袁晓凡,赵兵,王玉春.雪莲的研究进展.中草药,2004,35(12):1424-1426.
    [37] 麦军利,姜维.雪莲注射液的临床应用.中草药,1999,30(增刊):214.
    [38] 孙玉华,哈木拉提,张云珍.雪莲注射液的长期毒性研究.时珍国医国药,2005(2):98.
    [39] 乌拉孜别克.雪莲注射液环跳穴注射治疗坐骨神经痛32例.新疆中医药,1998,16(2):25.
    [40] 郑茂斌,罗庆军,朱晓平.雪莲注射液治疗关节炎.中国骨伤,2000,13(6):378.
    [41] 金钟,袁红,黄菁.雪莲注射液治疗肩周炎40例.抗炎作用研究,2003,21(4):14.
    [42] 谭义妹.雪莲注射液治疗风湿寒性关节痛18例.山西中医,1997,13(6):8.
    [43] 蔡绍晖,唐琼,陈嘉钰.复方雪莲烧伤膏促创面愈合、抗炎作用研究.中成药,1999,21(5):243-245.
    [44] 蔡绍晖,陈嘉钰,唐琼.复方雪莲烧伤膏抗菌活性的研究.华西药学杂志,1998,13(3):148-150.
    [45] 赵文,任永凤.雪莲通脉口服液含量测定的研究.中成药,1998,20(3):21-22.
    [46] 邓红,阳春年,王兆江.雪莲通脉丸治疗老年及老年前期冠心病51例效果观察.安徽中医学院学报,1992,11(3):15-17.
    [47] 黄霞萍,朱荣光.复方雪莲胶囊治疗痹证102例临床观察.江苏中医,2000,21(11):26-27.
    [48] 薛秀峰,张海茹,潘丽娜,等.雪莲及其注射液的指纹图谱研究.哈尔滨医科大学学报,2005,39(1):72-74.
    [49] 范志刚,麦军利,杨莉斌,等.微波技术对雪连中总黄酮浸出量影响的研究.中国民族医药杂志,2000 34(1):43-44.
    [50] 唐辉,刘金荣,洪成林等.新疆雪莲药酒中黄酮总甙的含量测定.农垦医学,1999,21(2):84-85.
    [51] 中华人民共和国卫生部药品标准.WS32823334298.
    [52] 王文芝.雪莲细胞培养组织中黄酮的含量测定.中草药,1997,28(11):654-656.
    [53] 庞志功 汪宝琪.西藏雪莲花中总黄酮含量测定研究.化学研究与应用,1995,7(1):102-104.
    [54] 郭喜红,张丹,于鲁海,等.HPLC法测定雪莲注射液中芦丁含量.中国药房,1997,8(3):132.
    [55] 苗爱东,孙殿甲,彭燕,等.HPLC测定雪莲注射液中紫丁香苷的含量.药物分析杂志,2003,23(4):289-290.
    [56] 薛秀峰,陈华山,熊志立,等.RP-HPLC法同时测定雪莲注射液中3种成分的含量.2005,22(5):363-366.
    [57] 俞敏倩,陈建民.高效相色谱法测定11种雪莲花中的紫丁香甙及芦丁.色谱,2001,19(3):243-244.
    [58] 李锐.中医方药的药动学研究.中药药理与临床,1991,7(1):35-40.
    [59] 邓富材,陈国华,邓世林,等.RP-HPLC测定老鼠血浆中芦丁的含量.药物分析杂志,2004,24(3):253-255.
    [60] 曹晓芝,袁成.高效液相色谱法测定血浆中羟乙基芦丁的浓度.中国医院药学杂志,1997,17(5):215-218.
    [61] Kazuo I, Takashi F, Yasuji K. Determination of rutin in human plasma by high-performance liquid chromatography utilizing solid-phase extraction and ultraviolet detection. J Chromatogr B, 2001, 25(1): 161-168.
    [62] 国家药典委员会.药物制剂人体生物利用度和生物等效性试验指导原则.中华人民共和国药典,2005年版(二部),附录173-176.
    [63] Shah VP, Midha KK, Hulse JD, et al. Bioanalytieal methods validation-a revisit with a decade of progress. Pharmaceutical research, 2000, 17(12): 1551-1557.
    [64] 萧参,陈坚行.生物药剂分析方法的认证.中国药学杂志,1993,24(7):425-426.
    [65] Karnes HT, March C, Precision, accuracy and data acceptance criteria in biopharmaeeutical analysis, Pharmaceutical research, 1993, 10(10): 1420-1422.

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址:北京市海淀区学院路29号 邮编:100083

电话:办公室:(+86 10)66554848;文献借阅、咨询服务、科技查新:66554700